1. Home
  2. NUWE vs BRTX Comparison

NUWE vs BRTX Comparison

Compare NUWE & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuwellis Inc.

NUWE

Nuwellis Inc.

HOLD

Current Price

$0.88

Market Cap

3.2M

Sector

Health Care

ML Signal

HOLD

Logo BioRestorative Therapies Inc. (NV)

BRTX

BioRestorative Therapies Inc. (NV)

HOLD

Current Price

$2.69

Market Cap

3.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUWE
BRTX
Founded
1999
1997
Country
United States
United States
Employees
N/A
14
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Managed Health Care
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.7M
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
NUWE
BRTX
Price
$0.88
$2.69
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.0M
202.6K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,270,000.00
$81,000.00
Revenue This Year
$11.14
$298.39
Revenue Next Year
$18.51
$64.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.08
$0.14
52 Week High
$6.40
$4.10

Technical Indicators

Market Signals
Indicator
NUWE
BRTX
Relative Strength Index (RSI) 43.23 62.80
Support Level $0.71 $0.22
Resistance Level $1.20 $4.10
Average True Range (ATR) 0.09 0.41
MACD 0.06 0.09
Stochastic Oscillator 18.82 65.76

Price Performance

Historical Comparison
NUWE
BRTX

About NUWE Nuwellis Inc.

Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

About BRTX BioRestorative Therapies Inc. (NV)

BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.

Share on Social Networks: